© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Clinafloxacin entered the scientific spotlight during the late 1980s and early 1990s. The rise of antimicrobial resistance fueled a search for stronger fluoroquinolones. Researchers saw promise in a subclass that could hit both Gram-positive and Gram-negative bacteria, especially as hospitals grappled with tricky infections. Drug makers steered clinafloxacin through tough preclinical and clinical testing, chasing a molecule that could outpace stubborn bugs like MRSA and Pseudomonas. By the mid-1990s, trials highlighted its broad reach and potent action, sparking hope. Practical challenges soon became clear: safety flags like phototoxicity and hypoglycemia affected trial participants. These issues would cloud its path, despite its raw power against many resistant strains.
Chemically, clinafloxacin belongs to the fluoroquinolone class, cousins to ciprofloxacin and levofloxacin. Its design trades a classic piperazine ring for a chlorine group at the C-8 position, bringing extra punch against tough bugs. Pharmaceutical labs focus on making this compound as bulk powder or as a base for injectable solutions. The powder is off-white to pale yellow, reflecting its core structure, and usually appears as a relatively stable crystalline solid. Some hospitals tested clinafloxacin in IV formulations. Oral forms existed on paper but stayed in the shadows, given safety concerns.
Clinafloxacin is a strong crystalline substance, melting between 250°C and 260°C. The chemical formula is C17H18ClFN4O4, with a molecular weight close to 396.8 g/mol. Its solubility profile matches that of other fluoroquinolones—freely soluble in dilute acids, sparingly soluble in water, and almost insoluble in non-polar solvents like chloroform. The molecule holds a chlorine atom at position C-8, increasing lipid solubility and cell penetration. Its pKa hovers around 6.2 for the carboxyl group and near 8.7 for the amine, impacting absorption and activity within the body.
Wherever clinafloxacin reaches research labs, quality specs matter. Purity often exceeds 98% by HPLC, with rigorous control on moisture (less than 0.5%) and specific optical rotation for identity checks. Color, appearance, and crystalline form get documented for traceability. Labs publish the compound’s batch number, molecular structure, analytical confirmation, and hazard warnings. Product labels feature chemical identifiers, storage instructions—usually keep tight and dry, below 25°C—and warnings about light sensitivity and potential toxicity.
Producing clinafloxacin starts by assembling the quinolone nucleus via classic multi-step organic syntheses. Early steps fuse halogenated benzoic acid derivatives with suitable amines and ketones under controlled temperature, catalysis, and pH. A typical route introduces the chloro group at C-8 using chlorinating agents, followed by careful cyclization and purification. Protecting groups help chemists handle reactive intermediates, especially during esterification or amidation. Recrystallization from ethanol or acetone brings the raw product closer to study-grade purity, and vacuum drying removes last traces of solvent.
The structure opens doors for chemical tweaking. N-alkylation, esterification, and halogen exchange allow fine-tuning of its pharmacokinetics and antimicrobial profile. By swapping halogen positions or adjusting ring substituents, chemists study how potency and selectivity change. Researchers also link clinafloxacin to carrier peptides or create prodrugs by modifying its carboxyl group—to target tissues or reduce toxicity. Some labs even conjugate the molecule to nanoparticles or lipids, chasing better delivery. Each change brings new challenges, as the delicate balance between activity and human safety never stays still.
Clinafloxacin also goes by other names in literature and supply catalogs. Synonyms include Sch 27899 and clinafloxacin hydrochloride. Some sources may call it by its research project code or under investigational trial IDs. Product packaging tends to stick with "clinafloxacin" for chemical clarity, while clinical development teams once explored trade names that faded as approval slowed.
Working with clinafloxacin means serious respect for lab safety. Sharp warnings cover skin and eye exposure risks, requiring gloves and goggles. Labs run extra ventilation for bulk handling, and spill control kits must sit nearby. Inhalation or accidental ingestion pulls swift first-aid or emergency steps, as animal studies show toxic effects at modest doses. Storage away from direct sunlight and heat preserves stability, and all waste routes must stay clear of public drains. Standard operating procedures walk lab techs through safe dispensing, weighing, and disposal—with checks for workplace contamination and exposure monitoring.
Doctors and researchers once saw clinafloxacin as a game-changer for nasty, hospital-acquired infections. Its action spans Gram-negatives—like E. coli and Pseudomonas—and Gram-positives, including stubborn MRSA. The compound knocks out some bacteria that shrug off older quinolones or even vancomycin. In infectious disease research, it still draws attention for biofilm penetration and synergy in combination therapy studies. Veterinary teams probe its power against animal infections, and basic science crowds look to it when designing experiments on bacterial resistance or drug uptake.
Drug developers in the 1990s lined up patient trials to gauge clinafloxacin’s real-world punch. Clinical programs targeted serious infections, community-acquired pneumonia, and skin infections where resistance threatened old standbys. Early results impressed on paper, especially against multi-drug-resistant strains. Large scale phase II and III trials brought the pitfall of safety issues, driving the industry to dial back enthusiasm. Still, research into how clinafloxacin disrupts bacterial DNA gyrase, its absorption kinetics, and ways to avoid dose-limiting side effects carries on. In recent years, academic teams have dusted off this compound, reassessing toxicology and searching for safer analogs through structural modification.
Toxicity held center stage as clinafloxacin moved from bench to bedside. Biggest worries: pronounced phototoxicity (severe sunburn reactions) and glucose metabolism changes, including low blood sugar in vulnerable patients. Animal studies flagged risks for cartilage damage, kidney stress, and blood disorders, echoing class effects of quinolones but turned up a notch. Clinical trial reports forced sponsors to update risk labels and limit participation to controlled settings. Toxicology teams today run expanded research on how clinafloxacin’s unique side groups impact off-target effects, hoping to map new boundaries for use or inspire smarter drug design.
The world’s need for new solutions against resistant bacteria keeps clinafloxacin in scientific conversations. Newer chemical tweaking, smarter delivery systems, or strict patient selection could someday let related compounds find a clinical foothold. Academic labs have rekindled interest by exploring clinafloxacin’s mechanisms and testing analogs with lighter safety profiles. Environmental and policy concerns about antibiotic stewardship weigh heavily now, pushing for cautious stepwise investigations. Data from the past mingle with modern hopes that deep structure-activity studies may yield next-generation agents—aiming to sidestep clinafloxacin’s early setbacks but retain its antimicrobial muscle.
Every now and then, I hear about an antibiotic making headlines not for being new, but for being pulled off the market or investigated for safety reasons. Clinafloxacin stands out as one of those stories. Developed in the late 1990s, it attracted interest for its strong effect against stubborn bacteria that shrugged off many of the older antibiotics. Doctors and researchers paid close attention, hoping it could help treat chronic or hard-to-beat infections. Clinafloxacin belongs to the fluoroquinolone family, a group of drugs with a reputation for knocking down a wide range of bacteria, both common and rare. In my experience working with medical communities, new antibiotics carry big responsibility: they can save lives when older medications fail, but they also come with risks that need careful review.
Bacterial infections that stop responding to common treatments are a problem I’ve seen countless times. In the lab and at the bedside, options narrow when bacteria become resistant. Clinafloxacin drew attention because it worked against infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant strains of Pseudomonas aeruginosa and Streptococcus pneumoniae. Many doctors saw it as a possible solution for patients with skin, soft tissue, or lung infections who had run out of other options. I remember conversations about its use for respiratory tract infections, such as hospital-acquired pneumonia, where standard drugs often fall short against aggressive germs. What set clinafloxacin apart was its activity against bacteria forming biofilms—a slimy barrier that protects them from regular antibiotics. For people facing devices or surgeries, biofilms can turn basic infections into months-long battles. That’s exactly the space where this drug found its intended use.
I’ve learned from doctors and pharmacists that every new medicine has growing pains. Clinical trials for clinafloxacin revealed some tough side effects. Patients experienced issues such as severe photosensitivity (heightened reaction to sunlight causing blisters and rashes) and changes in blood sugar. These weren’t just rare blips. Researchers saw enough cases to halt its commercial rollout in the United States and many other countries. For practitioners and patients, finding out a promising drug comes with new risks feels like hitting a wall just when you find a way through. By that point, the world was already dealing with a wave of antibiotic resistance, and losing a tool like this only raised the pressure on the remaining drugs.
Every time an antibiotic is sidelined, future treatment choices shrink a bit more. Resistance keeps growing and outpaces drug development, so losing a strong option like clinafloxacin leaves gaps in our arsenal. I’ve witnessed teams scramble to find combinations of old antibiotics just to keep infections in check. Several experts argue for reviving some shelved drugs for specific, monitored use in hospitals where nothing else works. Saving them for severe, life-threatening infections could keep these powerful medicines from widespread resistance buildup. In my view, using these drugs as a last line—paired with careful monitoring and research—could buy precious time while new treatments are developed.
What clinafloxacin’s story shows is that we can’t take antibiotics for granted. More research into safer alternatives, better diagnostics, and rapid resistance screening could offer answers for people faced with tough infections. I believe it’s time to reward companies and researchers for responsible drug design and for protecting what antibiotics we have left. We have to stay smart and careful—not just about using old drugs like clinafloxacin in the right handful of cases, but about keeping the entire system geared toward smarter infection control and stewardship. For anyone who’s had a brush with a tough infection, the value of having even one other option isn’t just clear—it’s personal.
Clinafloxacin belongs to a group of antibiotics called fluoroquinolones. These drugs pack a punch against tough bacterial infections, which sets a high bar. Many are eager to know what risks come with treatments that do so much heavy lifting. From my time working in health journalism and talking to folks who’ve relied on powerful antibiotics, questions often circle back to side effects. Understanding those risks goes a long way, whether someone works in a hospital, sits in a pharmacy, or takes these medications at home.
With clinafloxacin, some side effects seem mild but still bother people enough to bring up with their doctor. Nausea, diarrhea, and headaches tend to show up the most. Stomach upset crops up in conversation more often than anything else, especially if someone has a sensitive digestive system. Patients tell stories of meals interrupted by a sudden need for the bathroom or a dull ache in the forehead that just won’t fade. These side effects don’t usually end with lasting damage, but they steal away comfort and peace of mind.
Clinafloxacin has a knack for causing a few issues that demand more attention. Blood sugar swings can catch people off guard, especially if someone already struggles to keep diabetes in check. Low blood sugar brings the shakes, confusion, and sweats that no one forgets. On the other end, high blood sugar leaves patients feeling foggy and drained.
Alongside these, sun sensitivity jumps out as another sign to watch for. Even a quick walk on a bright day can lead to burns or rashes that take days to calm down. Those working outside or anyone who spends a lot of time outdoors needs solid advice—long sleeves, hats, and plenty of sunscreen. Skipping these steps can bring avoidable pain and trips to the doctor.
Doctors and pharmacists warn about tendon problems for good reason. Clinafloxacin belongs to the same family as other drugs linked to tendon swelling and even tears, especially in the Achilles tendon. A torn tendon changes lives, keeps people in bed, or strains finances thanks to missed work and rehab. I’ve seen athletes sidelined and older adults lose hard-won independence after a sudden injury linked to these meds.
Another red flag stems from clinafloxacin’s impact on the heart’s electrical system. A longer QT interval can open the door to heart rhythm troubles. If a person already deals with heart issues or takes several medications, the risk doesn’t stay small. Some pharmacists will flag this drug right away if a patient’s chart shows heart trouble or other risk factors.
Patients hold real power when they talk to their providers honestly about past problems with antibiotics or family history of tendon and heart troubles. Healthcare workers can catch early signs—muscle pain, odd heartbeats, rashes—and shift gears before a bad situation blooms. Extra blood tests and smarter sun habits matter. Providers can look to alternatives that keep risks low for people with complications.
Better education helps, too. The more people know about the possible downsides, the quicker they can act if something feels off. Simple advice and honest conversations beat small print warnings on prescription bottles every time.
Clinafloxacin belongs to a class of antibiotics known for tackling tough bacterial infections. Unlike over-the-counter medicine, it demands more attention to detail. Doctors often reserve it for hard-to-treat infections, especially when other options fail. Giving it the right way can mean the difference between a successful recovery and an avoidable setback.
Missing a dose or guessing at timing leaves infections with a chance to bounce back stronger. I’ve seen this even among friends who thought it made no difference if they took their medicine before sleep or after breakfast. In truth, antibiotics work best when blood levels stay steady. Skipping or stacking doses risks developing drug-resistant bacteria—an issue the World Health Organization labels as a threat to global health.
Doctors base their instructions on solid research and years of experience. For clinafloxacin, a discussion usually covers how much to take, how often, and for how long. Even the tiniest detail, like the time of day or with or without food, makes a difference. Taking the drug with plenty of water can help avoid stomach irritation, though each patient’s needs may change. Those with kidney problems, for instance, may need an adjusted dose.
Mixing any medication with alcohol rarely brings good results. Certain foods or supplements—especially those with calcium or iron—can interfere with how the drug gets absorbed. Spacing out these substances from the antibiotic by a few hours helps absorption. Grapefruit juice, known to interact with many medicines, should stay off the menu during treatment.
No joke—strong antibiotics sometimes pack a punch. Upset stomach, headaches, or rashes show up in some patients. Clinafloxacin brings a higher risk for certain side effects, such as sensitivity to sunlight or changes in blood sugar levels. Anyone who feels dizzy, notices heart palpitations, or develops new joint pain should let their healthcare team know right away. Catching these signals early leads to better outcomes.
Stopping treatment early might tempt people, especially as symptoms fade. I remember a relative who quit her antibiotics before the bottle ran out, convinced she was “all better.” She ended up back in the hospital within weeks. Bacteria that get exposed to only part of a drug dose can return and cause even worse problems. It sounds old-fashioned, but taking every pill counts.
Patients and doctors each play a role in fighting drug resistance. Patients ask questions, keep track of instructions, and talk about side effects. Doctors prescribe only when needed and check on patients to spot problems early. Hospitals track which bugs crop up and change antibiotics when necessary.
Spreading real information about smart antibiotic use pays off for everyone. Public health campaigns, easy-to-read prescriptions, and access to pharmacists set up more people for success. Families who know the risks find it much easier to stick with the plan—and prevent future infections from getting out of hand.
Clinafloxacin promised a lot in the world of antibiotics. Researchers saw its potential to fight tough bacterial infections, including strains that brush off older drugs. Yet, this medication never landed on pharmacy shelves for ordinary patients. Many people ask about its availability, especially as antibiotic resistance spreads. The reason has a lot to do with the hurdles a drug faces before anyone gets a prescription.
Back in the 1990s, scientists tested clinafloxacin on a range of infections. Test tubes showed it worked against certain bacteria, and clinical studies backed up some of those results. It was one of a handful of so-called "fluoroquinolones," a class that also includes drugs like ciprofloxacin and levofloxacin. These medicines get used for infections from pneumonia to urinary tract issues.
During clinical trials, patients who received clinafloxacin sometimes developed side effects not seen with other similar antibiotics. The most serious was a kind of low blood sugar called hypoglycemia, which in rare cases led to coma or death. Some people developed unusual skin reactions, especially after exposure to sunlight. These events raised red flags for the FDA and drug developers. Scientists have a responsibility to make sure that side effects do not outweigh benefits for patients. With antibiotics, the threshold is even higher, since safer alternatives often exist.
The world is full of stories about “game-changing” drugs. Most never make it past the final hurdle, and clinafloxacin became another example. Safety concerns mean doctors can’t write prescriptions for it, even though lab studies looked promising. From a public health standpoint, communities are already fighting resistance tied to overuse and misuse of many antibiotics in hospitals and clinics. Making sure new drugs are actually safer is not something negotiable.
Studies found that clinafloxacin caused both mild and life-threatening side effects in enough patients that companies pulled the plug. While it hasn’t disappeared entirely—researchers sometimes keep it in laboratory experiments or rare, carefully controlled situations—it does not get approved for day-to-day human use in the United States, Europe, or most other countries. This helps explain why hospitals do not keep it in stock, and why doctors cannot request it for their sickest patients. Clinical risks trumped its early promise.
Antibiotic resistance has become a health crisis. The CDC estimates at least 2.8 million antibiotic-resistant infections occur each year in the U.S., leading to at least 35,000 deaths. Every year, doctors look to the pipeline for new options. Old antibiotics sometimes don’t work as well, but rushing unsafe new ones to market can trigger catastrophes, harming fragile patients. Under strict rules, only two dozen or so new antibiotics have launched in the last decade, and many of those address only rare or specialized infections.
The answer goes beyond just developing new drugs quickly. Deep investment in research helps, so does better stewardship—limiting the use of existing drugs to cases where they’re absolutely necessary. Hospitals track prescriptions and push guidelines that protect both current and future patients. On the innovation side, governments and public agencies can offer support to nudge smarter, safer drug development. Hospitals and doctors can stay trained on spotting early trouble with new drugs. Patients play a role, too, always finishing prescriptions and never self-medicating with leftover antibiotics, since improper use drives resistance and makes drug failures more likely.
A big part of staying safe with any prescription comes down to knowing what blends and what clashes. Clinafloxacin, a fluoroquinolone antibiotic made to fight tough bacteria, doesn’t hit the pharmacy shelves often. Still, for those who end up on it, questions around drug interactions can’t get shrugged off. Mixing meds without checking always lands people in trouble—sometimes just with an upset stomach, sometimes with a trip to the ER.
Clinafloxacin isn’t new on the radar for infectious disease specialists, though it’s mostly found in studies instead of pill bottles. Just because it’s not widely prescribed doesn't mean it’s free from the risk of interactions. Take other fluoroquinolones, for example—ciprofloxacin, levofloxacin. Doctors spot patterns: metal-containing antacids, iron pills, and certain supplements can reduce antibiotic absorption, making them less useful. People grabbing a handful of daily vitamins or over-the-counter heartburn relief might unknowingly blunt their own treatment.
The risk isn’t just about less medicine getting through. Combining some antibiotics with blood sugar medication or heart rhythm drugs ramps up the chance of side effects—sometimes even dangerous rhythms or sudden blood sugar drops. Even without Clinafloxacin’s full dossier of interactions mapped out, it’s smart to look at anything that acts like it in the body.
Clinafloxacin, like its cousins, targets machinery inside bacteria to disrupt their life cycle. By its nature, it doesn’t just float through the body unchanged. Other medications ride the same chemical “roads," so there’s real competition. Calcium, magnesium, zinc and aluminum can hitch a ride in antacids, multivitamins, or laxatives, steering Clinafloxacin off course before it even gets absorbed. Fluoroquinolones sometimes trigger higher risk for seizures, especially mixed with drugs lowering seizure threshold or certain psychiatric meds.
On top of that, antibiotics like these can interact with the liver’s enzymes, changing how other drugs break down. Warfarin, a common blood thinner, can see its effects boosted or reduced, making bleeding or clots more likely. I once knew a patient who learned this the hard way—just a new antibiotic and suddenly his routine bloodwork turned dangerous. Medications for heart rhythm, like amiodarone or sotalol, need extra caution too, due to risk of a rare heart rhythm called torsades de pointes.
Digging through a list of meds feels tedious, but that grunt work keeps problems from cropping up. Real-world slips usually come from assumptions. Someone figures “it’s just an antibiotic,” and combines it with everything else on their kitchen counter. Next thing you know, the bug isn’t killed off, or something else kicks up side effects.
Doctors and pharmacists need to keep their guard up, reading through a person’s meds and asking non-judgmental questions about supplements, energy drinks, or the latest herbal trend. Some folks trust label instructions over a quick conversation, missing critical advice. Alert systems in medical records flag classic interactions, but not every health system keeps up with the latest data—especially with drugs less familiar in everyday practice.
A good fix always starts with honest talk. Bring in every bottle—prescription, over-the-counter, and supplement. Pharmacists carry valuable knowledge, often catching snags before doctors do. Getting the timing right matters: separating doses by a few hours or sometimes skipping a supplement can let the antibiotic work its best. Keeping a current list of medications, and checking back with each new prescription, saves time, money, and health in the long run.
Updates keep rolling out as researchers track down more real-life cases. If you’re on Clinafloxacin or any antibiotic you don’t recognize, dig for details, ask for pharmacist input, and never assume all combos are safe. What we don’t know yet still matters, and taking it seriously keeps doors open to recovery instead of complications.
| Names | |
| Preferred IUPAC name | 3-quinoxalin-6-yl-8-chloro-1-cyclopropyl-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| Other names |
TA-7284 CL-960 |
| Pronunciation | /klɪˌnæf.ləˈksə.sɪn/ |
| Identifiers | |
| CAS Number | 105956-29-8 |
| Beilstein Reference | 5275637 |
| ChEBI | CHEBI:37944 |
| ChEMBL | CHEMBL47092 |
| ChemSpider | 57313 |
| DrugBank | DB00574 |
| ECHA InfoCard | 100000012565 |
| EC Number | EC 4.2.1.81 |
| Gmelin Reference | 126578 |
| KEGG | D01260 |
| MeSH | D019821 |
| PubChem CID | 441130 |
| RTECS number | SN6175000 |
| UNII | H5F04552EG |
| UN number | UN1993 |
| Properties | |
| Chemical formula | C18H12ClFN4O4 |
| Molar mass | 401.812 g/mol |
| Appearance | Light yellow powder. |
| Odor | Odorless |
| Density | 1.67 g/cm³ |
| Solubility in water | Slightly soluble |
| log P | 1.74 |
| Acidity (pKa) | 5.7 |
| Basicity (pKb) | 8.43 |
| Dipole moment | 3.7743 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Clinafloxacin is 0 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -763.1 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -6132.4 kJ/mol |
| Pharmacology | |
| ATC code | J01MA14 |
| Hazards | |
| Main hazards | May cause irritation to skin, eyes, and respiratory tract; may cause allergic reactions; harmful if swallowed. |
| GHS labelling | GHS labelling: "Danger; H361, H302, H317, H319, H334, H341, H350, H373, P201, P261, P280, P308+P313, P405, P501 |
| Pictograms | 💊🦠🚫 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332: Harmful if swallowed, in contact with skin or if inhaled. |
| Precautionary statements | Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Use personal protective equipment as required. Avoid release to the environment. |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| Flash point | > Flash Point: 11.3±22.6 °C |
| Lethal dose or concentration | LD50 (rat, oral): 523 mg/kg |
| LD50 (median dose) | LD50: 150 mg/kg (oral, mouse) |
| NIOSH | Not Listed |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.5 g every 12 hours |
| Related compounds | |
| Related compounds |
Ciprofloxacin Difloxacin Enoxacin Fleroxacin Gatifloxacin Gemifloxacin Levofloxacin Lomefloxacin Moxifloxacin Nadifloxacin Norfloxacin Ofloxacin Tosufloxacin |
